REGULATORY

• Japan Panel to Review KalVista’s Oral HAE Drug, GSK’s Asthma Med, and More on Nov. 27
  November 14, 2025

• Chuikyo Backs Halving Profit Coefficient for Conditionally Approved Regenerative Medicines
  November 13, 2025

• Industry Opposes Deeper CEA Price Cuts for “Cost-Increase” Products
  November 13, 2025

• Pharma, Wholesalers Urge Drug Pricing Overhaul to Address Inflation: LDP Hearing
  November 13, 2025

• Ishin Presses Govt to Commit to OTC-Like Drug Reform by FY2026
  November 13, 2025

• Health Minister Says Govt Mulling Backing for Wholesaler Support
  November 13, 2025

• LDP Study Group Seeks Uniform 5% Drug Price Hike, Warns of US MFN Spillover
  November 12, 2025

• Japan’s 1st Biosimilars for Eylea, Actemra Get NHI Listing in November
  November 11, 2025

• MOF Pushes Stronger Use of CEA for Pricy Meds towards FY2026 Budget
  November 11, 2025

• Growth Strategy Council Seeks Stronger Drug Discovery Infrastructure in Economic Plan
  November 11, 2025

• LDP Kampo Caucus Chief Wary of Removing Insurance Coverage
  November 10, 2025

• LDP Panel Backs Support for Drug Wholesalers in Economic Package
  November 10, 2025

• Downstream Providers Decry Growing Negative Margins at Ryukaikon
  November 10, 2025

• Category A Priority Drugs Kept in Separate-Handling Clause under Distribution Guidelines
  November 10, 2025

• MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
  November 7, 2025

• Keytruda Faces 5th Price Cut under Special Re-Pricing; MSD Warns of Ripple Effects
  November 6, 2025

• Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen
  November 6, 2025

• MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
  November 6, 2025

• Reblozyl to Face 8% Cut, Vyloy 4% in February: CEA Adjustment
  November 6, 2025

• Servier’s Voranigo Skips November Listing; GSK, BMS Drugs Also Absent
  November 6, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• …
• Next ›
• 最終 »